Diabetes Management
Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Le | OTT - Dove Medical Press
Fri, 28 Oct 20221 min read Article
Overview
Javascript is curently disabled in your browser. Several features of this site wil not function whilst javascript is disabled.open aces to scientific and medical researchPapers PublishedOpen aces per-reviewed scientific and medical journals.Learn moreDove Medical Pres is a member of the OAI.Learn moreBulk reprints for the pharmaceutical industry.Learn moreWe ofer real benefits to our authors, including fast-track procesing of papers.Learn moreRegister your specific details and specific drugs of interest and we wil match the information you provide to articles from our extensive database and email PDF copies to you promptly.Learn moreBack to Journals » OncoTargets and Therapy » Volume 15 Authors Leung M , Rodrigues P, Roitman D Received 1 April 2022 Acepted for publication 9 August 2022 Published 28 October 2022 Volume 2022:15 Pages 1309—1315 DOI htps:/doi.org/10.2147/OT.S37024 Checked for plagiarism Yes Review by Single anonymous per review Per reviewer coments 2 Editor who aproved publication: Dr Sanjev Srivastava Mova Leung,1,2 Paulina Rodrigues,2 Daryl Roitman1 1Cancer Care Program, North York General Hospital, Toronto, Ontario, Canada; 2Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, CanadaCorespondence: Mova Leung, Email [email protected]Background: Diabetic ketoacidosis (DKA) is a rare complication of alpelisib, but cases of DKA are reported.
Key Information
Alpelisib’s safety in patients with long-standing, suboptimaly controled diabetes is unclear since clinical trials of alpelisib did not include them.Case: A case is presented on a patient with metastatic breast cancer and type 2 diabetes admited for DKA eleven days after starting alpelisib. Since DKA is implicated in antihyperglycemics that inhibit sodium-glucose cotransporter-2 (SGLT2) inhibitors, her empagliflozin was discontinued.
Summary
Alpelisib was also held since it was recently initiated. After the DKA resolved, she was discharged and restarte
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.